SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) July 1, 1999
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc. announced today that its
Diasensor noninvasive glucose monitor was displayed at
the recent meeting of the American Diabetes Association
in San Diego, CA. To gain marketing approval in the
United States, Biocontrol has begun a modular premarket
approval (PMA) application to the FDA by submitting the
first module on May 24, 1999. The FDA is expected to
respond to Biocontrol within 90 days of the submission
date. Additional information will be required to
complete the full modular PMA.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information and Exhibits.
(a) Financial Statements and Businesses Acquired - Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: June 24, 1999
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.429.0673 phone
1.412.279.9690 fax 1.412.279.5041 fax
BIOCONTROL'S DIASENSOR DISPLAYED AT AMERICAN DIABETES ASSOCIATION
ANNUAL MEETING
Pittsburgh, PA - July 1, 1999 - Biocontrol Technology, Inc.
(OTCBB:BICO) announced today that its Diasensor noninvasive
glucose monitor was displayed at the recent meeting of the
American Diabetes Association in San Diego, CA. Currently
marketed in the 15-country European Union, the Diasensor is the
first commercially available painless noninvasive monitor for
glucose measurements in people with diabetes.
To gain marketing approval in the United States, Biocontrol
has begun a modular premarket approval (PMA) application to the
FDA by submitting the first module on May 24, 1999. The FDA is
expected to respond to Biocontrol within 90 days of the
submission date. Additional information will be required to
complete the full modular PMA.
The American Diabetes Association's annual meeting, which
was held this year June 19 through June 22, attracts thousands of
physicians, nurses, educators, scientists, suppliers and other
miscellaneous attendees. David Purdy, Biocontrol's president,
who attended the meeting, said that advances in noninvasive
glucose testing were in evidence and that "it was gratifying to
our company to be the first manufacturer there that has received
regulatory approval to market a truly noninvasive glucose
monitor." The CE Mark, which permits the company to sell the
devices in the European Union, was awarded to Biocontrol for the
sensor in March 1998.
Biocontrol Technology has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture
of biomedical devices and environmental products. Subsidiary
Diasensor.com, Inc., also located in Pittsburgh, PA, markets the
Diasensor. Diasensor.com owns the patent, marketing and
distribution rights to the sensor while Biocontrol has the
exclusive rights to the research and development and
manufacturing of the sensor.
WEBSITE: www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER: 1.800.357.6204
